Roche launches Hemophilia A drug


Roche has launched Emicizumab under the Hemlibra brand in India for the preventive treatment of Hemophilia A, a hereditary disorder in which a person's blood does not coagulate properly. Hemlibra is the first weekly injection of subcutaneous prophylaxis demonstrated to prevent or reduce the frequency of bleeding episodes and improve quality of life, Roche said in a statement. All current prophylactic treatment options for people with Hemophilia A with factor VIII inhibitors require intravenous infusions several times a week, he added.


Source link